Xin Lang Cai Jing·2025-09-09 03:16Company Overview - Tiger Med is located in Hangzhou, Zhejiang Province, and was established on December 15, 2004, with its IPO on August 17, 2012 [1] - The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products, covering I to IV phase clinical trial technical services, data management and statistical analysis, registration application, clinical trial site services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1] Financial Performance - For the first half of 2025, Tiger Med reported a revenue of 3.25 billion yuan, a year-on-year decrease of 3.21%, and a net profit attributable to shareholders of 383 million yuan, down 22.22% year-on-year [2] - The company has cumulatively distributed 2.458 billion yuan in dividends since its A-share listing, with 1.154 billion yuan distributed over the past three years [3] Stock Performance - As of September 9, Tiger Med's stock price was 65.83 yuan per share, with a market capitalization of 56.681 billion yuan [1] - Year-to-date, the stock price has increased by 21.18%, but it has seen a decline of 0.63% over the last five trading days and 1.78% over the last twenty days [1] Shareholder Information - As of June 30, 2025, the number of shareholders was 51,500, a decrease of 4.14% from the previous period [2] - The top ten circulating shareholders include notable funds, with changes in their holdings indicating varying levels of investment interest [3]